Tin tức & Cập nhật

A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.

The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.

A recent study in Bangladesh recommends the inclusion of an individual’s unmet need assessment in every treatment protocol of breast cancer to achieve better treatment outcomes.

Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

First-line treatment with alectinib appears to produce sustained clinical benefit in Asian patients with advanced, ALK-positive nonsmall cell lung cancer (NSCLC) through 5 years of follow-up, according to long-term data from the phase III ALESIA presented at the ESMO Asia Congress 2022.

Treatment with SCC244, a novel small molecule inhibitor of the enzyme MET kinase, appears to help overcome the resistance to tyrosine kinase inhibitors (TKI) mediated by MET amplification in nonsmall cell lung cancer (NSCLC), reports a new study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

The addition of radiation therapy to chemotherapy may be more detrimental than beneficial in patients with resectable stage III nonsmall‐cell lung cancer (NSCLC), being associated with a heightened risk of severe cardiac events, as shown in a study.